Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. 1989

D E Nix, and W A Watson, and M E Lener, and R W Frost, and G Krol, and H Goldstein, and J Lettieri, and J J Schentag
School of Pharmacy, State University of New York, Buffalo.

The effect of an antacid (Maalox) and ranitidine administration on the absorption of ciprofloxacin was evaluated in healthy male volunteers who were enrolled in three separate studies. Each study was designed at a three- or four-period crossover and included the administration of 750 mg ciprofloxacin alone as a control treatment. Treatments that were evaluated included the administration of ciprofloxacin 5 to 10 minutes, 2 hours, 4 hours, and 6 hours after a single 30 ml dose of antacid; the administration of antacid 2 hours after ciprofloxacin was given; and the administration of ciprofloxacin 2 hours after a 200 mg ranitidine tablet. Administration of antacid within 4 hours before ciprofloxacin dose resulted in a significant decrease in ciprofloxacin absorption (p less than 0.05). Percentages of relative bioavailability compared with control values were 15.1%, 23.2%, and 70% for the 5 to 10 minute, 2 hour, and 4 hour antacid pretreatments, respectively. Administration of antacid 6 hours before or 2 hours after the ciprofloxacin dose did not affect absorption. Ranitidine did not alter ciprofloxacin absorption. Antacids that contain magnesium and aluminum salts may reduce the absorption of ciprofloxacin. The extent of this interaction appears to increase as the time between administration of the two drugs decreases. Ranitidine is suggested as an alternative to antacids for patients receiving treatment with ciprofloxacin.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D008274 Magnesium A metallic element that has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. It is important for the activity of many enzymes, especially those involved in OXIDATIVE PHOSPHORYLATION.
D008276 Magnesium Hydroxide An inorganic compound that occurs in nature as the mineral brucite. It acts as an antacid with cathartic effects. Brucite,Magnesium Hydrate,Magnesium Hydroxide (Mg(OH)4),Hydrate, Magnesium,Hydroxide, Magnesium
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D011899 Ranitidine A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers. AH-19065,Biotidin,N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine,Ranisen,Ranitidin,Ranitidine Hydrochloride,Sostril,Zantac,Zantic,AH 19065,AH19065,Hydrochloride, Ranitidine
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

D E Nix, and W A Watson, and M E Lener, and R W Frost, and G Krol, and H Goldstein, and J Lettieri, and J J Schentag
April 1992, Antimicrobial agents and chemotherapy,
D E Nix, and W A Watson, and M E Lener, and R W Frost, and G Krol, and H Goldstein, and J Lettieri, and J J Schentag
October 1979, American journal of hospital pharmacy,
D E Nix, and W A Watson, and M E Lener, and R W Frost, and G Krol, and H Goldstein, and J Lettieri, and J J Schentag
December 1990, Antimicrobial agents and chemotherapy,
D E Nix, and W A Watson, and M E Lener, and R W Frost, and G Krol, and H Goldstein, and J Lettieri, and J J Schentag
October 1992, Antimicrobial agents and chemotherapy,
D E Nix, and W A Watson, and M E Lener, and R W Frost, and G Krol, and H Goldstein, and J Lettieri, and J J Schentag
June 1977, The New England journal of medicine,
D E Nix, and W A Watson, and M E Lener, and R W Frost, and G Krol, and H Goldstein, and J Lettieri, and J J Schentag
May 1989, Antimicrobial agents and chemotherapy,
D E Nix, and W A Watson, and M E Lener, and R W Frost, and G Krol, and H Goldstein, and J Lettieri, and J J Schentag
January 1979, Arzneimittel-Forschung,
D E Nix, and W A Watson, and M E Lener, and R W Frost, and G Krol, and H Goldstein, and J Lettieri, and J J Schentag
June 1979, American journal of hospital pharmacy,
D E Nix, and W A Watson, and M E Lener, and R W Frost, and G Krol, and H Goldstein, and J Lettieri, and J J Schentag
October 1993, Antimicrobial agents and chemotherapy,
D E Nix, and W A Watson, and M E Lener, and R W Frost, and G Krol, and H Goldstein, and J Lettieri, and J J Schentag
March 2016, Pulmonary circulation,
Copied contents to your clipboard!